Single-administered GnRH agonist as luteal phase support in insemination cycles: a randomized controlled trial.

Leppänen R, Tinkanen H, Huhtala H, Ahinko K

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology24 Mar 2022Cited by 1 (Europe PMC)

PMID35323085DOI10.1080/09513590.2022.2054984PepBankPUB-35323085

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients undergoing IUI, live birth rates did not significantly differ with triptorelin versus no luteal support (7.9 versus 12.1%).
In plain wordsIn patients undergoing IUI, live birth rates did not differ significantly with triptorelin versus no luteal support.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLive birth rate
Study
n = 163
Comparator
No luteal phase support
Analysis
Primary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg once · subcutaneousAs given in this study (human).
Measurements
Live birth rate
7.9%
triptorelin group
Live birth rate
12.1%
control group
Source sentences
Summary
Overall, the live birth rate was lower in the triptorelin group compared to the control group (7.9 vs. 12.1%; p = .297).
3 context sentences(design, population, supporting numbers)
Summary · context
Altogether 251 IUI cycles in 163 patients were randomized to triptorelin and a control group between January 2017 and April 2019.
Summary · context
In the triptorelin group, the participants had a single administration of a subcutaneous GnRH agonist triptorelin 0.1 mg at the time of implantation.
Summary · context
In the control group, there was no luteal phase support.
Report a problemFND-3532308501
02HumanRandomized controlled trialEfficacy outcome
In patients undergoing IUI, clinical pregnancy rates were 12.6% with triptorelin versus 13.7% without luteal support.
In plain wordsIn patients undergoing IUI, clinical pregnancy rates were 12.6% with triptorelin versus 13.7% without luteal support.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseClinical pregnancy rate
Study
n = 163
Comparator
No luteal phase support
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg once · subcutaneousAs given in this study (human).
Measurements
Clinical pregnancy rate
12.6%
triptorelin group
Clinical pregnancy rate
13.7%
control group
Source sentences
Summary
The clinical pregnancy rates were 12.6 and 13.7%, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Altogether 251 IUI cycles in 163 patients were randomized to triptorelin and a control group between January 2017 and April 2019.
Summary · context
In the triptorelin group, the participants had a single administration of a subcutaneous GnRH agonist triptorelin 0.1 mg at the time of implantation.
Summary · context
In the control group, there was no luteal phase support.
Report a problemFND-3532308502
03HumanRandomized controlled trialSafety outcome
In patients undergoing IUI, miscarriages occurred in 2.4% with triptorelin and none without luteal support.
In plain wordsIn patients undergoing IUI, miscarriages occurred in 2.4% with triptorelin and none without luteal support.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseMiscarriage rate
Study
n = 163
Comparator
No luteal phase support
Analysis
Secondary
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg once · subcutaneousAs given in this study (human).
Measurements
Miscarriage rate
2.4%
triptorelin group
Miscarriage rate
0%
control group
Source sentences
Summary
There were 2.4% miscarriages in the triptorelin group and no miscarriages in the control group.
3 context sentences(design, population, supporting numbers)
Summary · context
Altogether 251 IUI cycles in 163 patients were randomized to triptorelin and a control group between January 2017 and April 2019.
Summary · context
In the triptorelin group, the participants had a single administration of a subcutaneous GnRH agonist triptorelin 0.1 mg at the time of implantation.
Summary · context
In the control group, there was no luteal phase support.
Report a problemFND-3532308503
04HumanRandomized controlled trialEfficacy outcome
In letrozole-stimulated IUI cycles, live birth rates were lower with triptorelin versus no luteal support (0 versus 14.7%).
In plain wordsIn letrozole-stimulated IUI cycles, live birth rates were lower with triptorelin than without luteal support.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreaseLive birth rate with letrozole stimulation
Study
n: not reported in source
Comparator
No luteal phase support
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg once · subcutaneousAs given in this study (human).
Measurements
Live birth rate
0%
triptorelin group, letrozole stimulation
Live birth rate
14.7%
control group, letrozole stimulation
Source sentences
Summary
Ovarian stimulation with letrozole was associated with lower LBR among the triptorelin group, in comparison to the control group (0 vs. 14.7%, p = .020).
3 context sentences(design, population, supporting numbers)
Summary · context
Altogether 251 IUI cycles in 163 patients were randomized to triptorelin and a control group between January 2017 and April 2019.
Summary · context
In the triptorelin group, the participants had a single administration of a subcutaneous GnRH agonist triptorelin 0.1 mg at the time of implantation.
Summary · context
In the control group, there was no luteal phase support.
Report a problemFND-3532308504
05HumanRandomized controlled trialEfficacy outcome
In IUI cycles stimulated with letrozole and gonadotrophin, live birth rates did not significantly differ with triptorelin versus control (15.9 versus 8.3%).
In plain wordsIn IUI cycles with letrozole and gonadotrophin, live birth rates did not differ significantly with triptorelin versus no luteal support.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLive birth rate with letrozole and gonadotrophin
Study
n: not reported in source
Comparator
No luteal phase support
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
0.1 mg once · subcutaneousAs given in this study (human).
Measurements
Live birth rate
15.9%
triptorelin group, letrozole plus gonadotrophin
Live birth rate
8.3%
control group, letrozole plus gonadotrophin
Source sentences
Summary
In contrast, when gonadotrophin was added to the letrozole, LBR was almost doubled compared to the control group (15.9 vs. 8.3%, p = .341).
3 context sentences(design, population, supporting numbers)
Summary · context
Altogether 251 IUI cycles in 163 patients were randomized to triptorelin and a control group between January 2017 and April 2019.
Summary · context
In the triptorelin group, the participants had a single administration of a subcutaneous GnRH agonist triptorelin 0.1 mg at the time of implantation.
Summary · context
In the control group, there was no luteal phase support.
Report a problemFND-3532308505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.